Lou Niles joins Being Patient Live Talks to discuss his experience taking part in the donanemab clinical trial. The monoclonal antibody drug was revealed to have promising results in late 2023 and is currently awaiting FDA approval. Now retired, Niles previously served as an army officer, a combat helicopter pilot in Vietnam, and as a firefighter and paramedic in San Diego. Because his mother died from Alzheimer’s, he was aware that he could be susceptible to cognitive decline, which led him to do a 23&Me DNA test a decade ago. The test revealed that he had one mutation associated with a higher risk for Alzheimer’s. That’s why, when he saw that there was an Alzheimer’s study in Orlando, FL, where he currently lives, Niles decided to participate. Over the course of the trial, he discovered that he indeed has cognitive decline and amyloid in his brain. In the talk, Niles will speak about his experience with cognitive decline and participating in the donanemab trial. Watch now to learn more about the clinical trial experience with MAB drugs. ------------ If you loved watching this Live Talk, visit our website to find more of our Alzheimer’s coverage and subscribe to our newsletter: https://www.beingpatient.com/ Follow Being Patient: Twitter: https://twitter.com/Being_Patient_ Instagram: https://www.instagram.com/beingpatientvoices/ Facebook: https://www.facebook.com/beingpatientalzheimers LinkedIn: https://www.linkedin.com/company/being-patient

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related